ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0781

Phenotypic and Functional Characterisation of Synovial Fluid-derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Abstract Number: 0551

Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis
Abstract Number: 1385

Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs
Abstract Number: 1146

Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus
Abstract Number: 1601

Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA
Abstract Number: 1645

Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Abstract Number: 1087

Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
Abstract Number: 0763

Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Abstract Number: 1792

Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Abstract Number: 1510

Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Abstract Number: 1625

Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Abstract Number: 1698

Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Abstract Number: 0421

Polymyalgia Rheumatica Is Associated with Later Menopause: An Observational Study
Abstract Number: 0659

Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Abstract Number: 0349

Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].